Xbrane Biopharma: Partner announced for Opdivo biosimilar - Redeye

Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development as it improves the company's financial position. Under the agreement, Xbrane will receive an upfront payment of USD10m, along with potential milestone payments of USD3m and double-digit royalties on future sales. The partner, Intas Pharmaceuticals, will finance and manage the clinical and regulatory development of Xdivane.

Länk till analysen i sin helhet: https://www.redeye.se/research/1058608/xbrane-biopharma-partner-announced-for-opdivo-biosimilar?utm_source=finwire&utm_medium=RSS